Basilea Reports Improved Financial Results In Half-Year 2017 Driven By Growing Product Sales; Significant Progress On Partnering And Development Programs
Published: Aug 10, 2017
Basel, Switzerland, August 10, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the first half of financial year 2017 with product sales from Cresemba® (isavuconazole) and Zevtera®/Mabelio® (ceftobiprole) in Europe increased to CHF 9.8 million (H1 2016: CHF 1.9 million; +416% year-on-year) plus royalties on U.S. Cresemba sales of CHF 5.2 million (H1 2016: CHF 3.0 million; +73%). Total revenue amounted to CHF 46.2 million (H1 2016: CHF 29.7 million; +56%). Basilea reported CHF 253.1 million in cash and investments as of June 30, 2017 and a significantly reduced operating loss of CHF 17.7 million in the first half-year (H1 2016: CHF 24.8 million; -29%).